Inquiry Form
Select One or Multiple Products for Inquiry
| Product | Indication | Segment/Class | COA | GMP | DML | DMF | |
| BENDAMUSTINE HCL | Chronic lymphocytic leukemia (CLL) |
Alkylating agent |  |
|
|
|
|
| TROPICAMIDE | Pupil dilation for eye exams | Anticholinergic | |
|
|
|
|
| TENOFOVIR ALAFENAMIDE FUMARATE |
HIV infection, hepatitis B virus (HBV) infection |
Antiretroviral, Antiviral | |
|
|
|
|
| LEVOSIM ENDAN | Acute heart failure, decompensated heart failure |
Calcium sensitizer | |
|
|
|
|
| BRINZOLAMIDE | Glaucoma, ocular hypertension |
Carbonic anhydrase inhibitor |
|
|
|
|
|
| APIXABAN | Venous thromboembolism prevention |
Cardiology | |
|
|
|
|
| IVABRADINE HCL | Heart failure. angina | Cardiology | |
|
|
|
|
| MILRINONE BASE/HCL | Heart failure | Cardiology | |
|
|
|
|
| MILRINONE LACTATE | Heart failure | Cardiology | |
|
|
|
|
| PEMAFIBRATE | Dyslipidemia | Cardiology | |
|
|
|
|
| RIVAROXABAN | Venous thromboembolism prevention |
Cardiology | |
|
|
|
|
| SACUBITRIL +VALSARTAN | Heart failure | Cardiology | |
|
|
|
|
| TICAGRFLOR BASE/HCL | Acute coronary syndrome prevention |
Cardiology | |
|
|
|
|
| VERICUGAT | Heart failure, chronic kidney disease |
Cardiology, Nephrology |
|
|
|
|
|
| RIBOCICLIB | Breast cancer, hormone receptor-positive, HER2- negative |
CDK4/6 Inhibitor | |
|
|
|
|
| TAPINAROF | Plaque psoriasis | Dermatology | |
|
|
|
|
| ALOGLIPTIN BENZOATE | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| CANAGLIFLOZIN | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| DAPAGLIFLOZIN PROPANE | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| DULAGLUTIDE | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| EMPAGLIFLOZIN | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| ERTUGLIFLOZIN L— PYROGLU | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| IPRAGLIFLOZIN L-PROLINE | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| LINAGLIPTIN | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| OMARIGL1PTIN | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| SAXAGLIPTIN HCL/HYDRATE | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| SEMAGLUTIDE | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| SITAGLIPTIN PHOSPHATE | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| SOTAGLIFLOZIN | Type 1 diabetes mellitus | Endocrinology | |
|
|
|
|
| TENELIGLIPTIN | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| TRELAGLIPTIN SUCCINATE | Type 2 diabetes mellitus | Endocrinology | |
|
|
|
|
| SPARSENTAN | Focal segmental glomerulosclerosis (FSGS), |
Endothelin Receptor Antagonist and Angiotensin II Receptor Blocker |
|
|
|
|
|
| OBETICHOLIC ACID | Primary biliary cholangitis | Gastroenterology | |
|
|
|
|
| TEDUGLUTIDE | Short bowel syndrome | Gastroenterology | |
|
|
|
|
| VONOPRAZAN FUMARATE | Gastroesophageal reflux disease |
Gastroenterology | |
|
|
|
|
| LINZAGOLIX | Endometriosis, Uterine Fibroids |
GnRH receptor antagonist |
|
|
|
|
|
| ELAGOLIX SODIUMELAGOLIX SODIUM | Endometriosis, uterine fibroids |
Gynecology | |
|
|
|
|
| RUXOLITINIB | Myelofibrosis, polycythemia vera |
Hematology | |
|
|
|
|
| ROXADUSTAT | Anemia associated with chronic kidney disease (CKD) |
HIF-ProIyI Hydroxylase Inhibitor |
|
|
|
|
|
| PITAVASTATIN CALCIUM | Hypercholesterolemia, prevention of cardiovascular events |
HMG-CoA reductase inhibitor (Stating) |
|
|
|
|
|
| BRINCIDOFOVIR | Antiviral therapy for CMV infections |
Infectious diseases | |
|
|
|
|
| MOLNUPIRAVIR | Oral treatment for COVID-19 | Infectious diseases | |
|
|
|
|
| RITLECITINIB TOSYLATE | Rheumatoid arthritis, atopic dermatitis |
JAK Inhibitor | |
|
|
|
|
| PEFICITINIB HYDROBROMIDE |
Rheumatoid arthritis | Janus Kinase (JAK) Inhibitor |
|
|
|
|
|
| LIFITEGRAST | Dry eye disease | Lymphocyte function- associated antigen 1 (LFA 1) antagonist |
|
|
|
|
|
| IMEGLIMIN HCL | Type 2 diabetes mellitus | Mitochondrial bioenergetics modulator |
|
|
|
|
|
| VAVACAMTEN | Hypertrophic cardiomyopathy |
Myosin inhibitor | |
|
|
|
|
| DAPRODUSTAT | Anemia associated with chronic kidney disease |
Nephrology | |
|
|
|
|
| FINERENONE | Chronic kidney disease, heart failure |
Nephrology, Cardiology |
|
|
|
|
|
| *EZOLINETANT | Vasomotor symptoms associated with menopause, |
Neurokinin 3 (NK3) receptor antagonist |
|
|
|
|
|
| CLOBAZAM | Epilepsy | Neurology | |
|
|
|
|
| MIROGABALIN BESYLATE | Fibromyalgia | Neurology | |
|
|
|
|
| DACLATASVIR | Chronic hepatitis C virus (HCV) infection |
WS5Ainibitoc | |
|
|
|
|
| VELPATASVIR | Chronic hepatitis C virus (HCV) infection |
NSSA inhibitor | |
|
|
|
|
| LEDIPASVIR COPOVIDONE | Chronic hepatitis C virus (HCV) infection |
NSW A inhibitor | |
|
|
|
|
| SOTORASIB | Non-small cell lung cancer | Oncology | |
|
|
|
|
| SUNITINIB | Renal cell carcinoma, gastrointestinal stromal tumor |
Oncology | |
|
|
|
|
| TRAMETINIB | Melanoma, non-small cell lung cancer |
Oncology | |
|
|
|
|
| TUCATINIIB | Solid tumors with FGFR genetic alterations |
Oncology | |
|
|
|
|
| VENCLEXTA | Chronic lymphocytic leukemia |
Oncology | |
|
|
|
|
| GEFAPIXANT CITRATE | Chronic cough | P2X3 Receptor Antagonist |
|
|
|
|
|
| LATANOPROST | Glaucoma, ocular hypertension |
Prostaglandin analog | |
|
|
|
|
| FLIBANSERIN | Hypoactive sexual desire disorder |
Psychiatry | |
|
|
|
|
| FLUPENTIXOL DECANOATE |
Schizophrenia | Psychiatry | |
|
|
|
|
| FLUPENTIXOL HCL | Schizophrenia | Psychiatry | |
|
|
|
|
| FLUPHENAZINE DECANOATE |
Schizophrenia | Psychiatry | |
|
|
|
|
| NITRAZEPAM | Anxiety disorders, insomnia | Psychiatry | |
|
|
|
|
| ZOLPIDEM TARTRATE | Insomnia | Psychiatry | |
|
|
|
|
| ZOPICLONE | Insomnia | Psychiatry | |
|
|
|
|
| BARICITINIB | Rheumatoid arthritis | Rheumatoid arthritis | |
|
|
|
|
| DEUCRAVACITINIB | Rheumatoid arthritis | Rheumatology | |
|
|
|
|
| FILGOTINIB BASE/MALEATE |
Rheumatoid arthritis, Crohn’s disease |
Rheumatology | |
|
|
|
|
| TOFACITINIB CITRATE | Rheumatoid arthritis | Rheumatology | |
|
|
|
|
| UPADACITINIB HEMI. | Rheumatoid arthritis, psoriatic arthritis |
Rheumatology | |
|
|
|
|
| BEXAGLIFLOZIN | Type 2 diabetes mellitus | Rheumatology | |
|
|
|
|
| REMOGLVLOZN ETABONATE |
Type 2 diabetes mellitus | Sodium-glucose co- transporter 2 (SGLT2) Inhibitor |
|
|
|
|
|
| LUSEOGLIF LOZIN | Type 2 diabetes mellitus | Sodium-glucose co- transporter 2 (SGLT2) Inhibitor |
|
|
|
|
|
| RIOCIGUAT | Pulmonary arterial hypertension (PAH) |
Sodium-glucose co- transporter 2 (SGLT2) Inhibitor |
|
|
|
|
|
| POSACONAZOLE | Fungal infections | Triazole antifungal | |
|
|
|
|
| DOTINURAD | Hyperuricemia associated with gout |
Uricosuric Agent | |
|
|
|
|
| VI8EGRON | Overactive bladder syndrome |
Urology | |
|
|
|
|
| TOPIROXOSTAT | Hyperuricemia associated with gout |
Xanthine oxidase inhibitor |
|
|
|
|
|
| SOFOSBUVIR | Chronic Hepatitis C virus (HCV) infection | Nucleotide analog NSW B polymerase inhibitor |
|
|
|
|
|
| ABEMACICLIB | Breast cancer | Oncology | |
|
|
|
|
| ACALABRUTINIB | Mantle cell lymphoma | Oncology | |
|
|
|
|
| AFATINIB | Non small cell lung cancer | Oncology | |
|
|
|
|
| ALPELISIB | Breast cancer | Oncology | |
|
|
|
|
| BINIMETINIB | Melanoma | Oncology | |
|
|
|
|
| BOSUTINIB | Chronic myelogenous leukemia |
Oncology | |
|
|
|
|
| BRIGATINIB | Non-small cell lung cancer | Oncology | |
|
|
|
|
| CABOZANTINIB | Renal cell carcinoma, hepatocellular carcinoma |
Oncology | |
|
|
|
|
| CAPMATINIB | Non small cell lung cancer | Oncology | |
|
|
|
|
| DACOMITINIB | Non small cell lung cancer | Oncology | |
|
|
|
|
| DASATINIB | Chronic myelogenous leukemia |
Oncology | |
|
|
|
|
| FRDAFITINIB | Urothelial carcinoma | Oncology | |
|
|
|
|
| IBRUTINIB | Mantle cell lymphoma, chronic lymphocytic leukemia |
Oncology | |
|
|
|
|
| LAPATINIB | Breast cancer | Oncology | |
|
|
|
|
| LAROTRECTINIB | Solid tumors with NTRK gene fusion |
Oncology | |
|
|
|
|
| LENVATINIB | Thyroid cancer, liver cancer | Oncology | |
|
|
|
|
| LORATINIB | Non small cell lung cancer | Oncology | |
|
|
|
|
| NERATINIB | Breast cancer | Oncology | |
|
|
|
|
| NIRAPARIB | Ovarian, fallopian tube, or primary peritoneal cancer |
Oncology | |
|
|
|
|
| OLAPARIB | Ovarian, breast, prostate cancer |
Oncology | |
|
|
|
|
| OSIMERTINIB | Non-small cell lung cancer | Oncology | |
|
|
|
|
| PALBOCICLIB | Breast cancer | Oncology | |
|
|
|
|
| PAZOPANIB | Kidney cancer, soft tissue sarcoma |
Oncology | |
|
|
|
|
| PEMIGATINIB | Cholangiocarcinoma | Oncology | |
|
|
|
|
| PONATINIB | Chronic myelogenous leukemia |
Oncology | |
|
|
|
|
| PRALSETINIB | Solid tumors with MET alterations |
Oncology | |
|
|
|
|
| REGORAFENIB | Colorectal, liver, gastrointestinal stromal cancer |
Oncology | |
|
|
|
|
| RELUGOLIX | Prostate cancer | Oncology | |
|
|
|
|
| REPOTRECTINIB | Solid tumors with ROS1 or NTRK gene fusion |
Oncology | |
|
|
|
|
| RUXAPARIB | Ovarian, fallopian tube, or primary peritoneal cancer |
Oncology | |
|
|
|
|
| SARACATINIB | Solid tumors with MET gene amplification | Oncology | |
|
|
|
|
| SORA*ENIB | Kidney cancer, liver cancer | Oncology | |
|
|
|